APLMW Overview

Nasdaq Compliance: Apollomics Inc. has received confirmation from Nasdaq that it is in compliance with listing requirements, leading to the cancellation of its appeal hearing regarding a previous delisting notification.

Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with its lead drug candidate, vebreltinib, currently in Phase 2 trials for treating non-small cell lung cancer and other advanced tumors.

Trading Halt Announcement: Nasdaq announced a trading halt for Apollomics Inc., Ltd. on September 17, 2025, at 14:37:17 Eastern Time due to a request for additional information from the company.

Current Share Prices: The last recorded sale price for Apollomics' ordinary shares was $18.4331, while the warrants were priced at $0.0191, with trading remaining halted until the company complies with Nasdaq's information request.

Strategic Collaboration: Apollomics Inc. has partnered with LaunXP to develop vebreltinib in combination with an EGFR inhibitor, receiving a $10 million upfront payment and aiming to expand its clinical dataset for treating non-small cell lung cancer (NSCLC).

Financial Overview: As of December 31, 2024, Apollomics reported $9.8 million in cash, a significant reduction in net loss compared to the previous year, and plans to focus resources on vebreltinib for patients with MET amplification, ensuring operational funding through early 2026.

Collaboration Announcement: Apollomics has partnered with LaunXP to develop and commercialize vebreltinib, a c-Met inhibitor combined with an EGFR inhibitor for treating non-small cell lung cancer (NSCLC) in Asia, excluding mainland China, Hong Kong, and Macau.

Financial Terms: Apollomics will receive $10 million upfront, potential pre-commercial milestones of up to $50 million, and royalties on net product sales as part of the agreement.

Trial Results: Apollomics Inc. announced that its Phase 3 trial of uproleselan for relapsed or refractory acute myeloid leukemia did not show a favorable benefit compared to chemotherapy alone, with median overall survival being lower in the uproleselan group (9.3 months) than in the control group (14.3 months).

Future Plans: The company plans to conclude the uproleselan program and submit full trial results for presentation at a future medical conference, while also focusing on its lead oncology program, vebreltinib, which is currently in clinical trials.

Regaining Compliance: Apollomics Inc. has regained compliance with Nasdaq's minimum bid price requirement, confirming that its Class A ordinary shares have maintained a closing bid price of $1.00 or greater for ten consecutive business days.

Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, including its lead program vebreltinib, a selective c-Met inhibitor currently in Phase 2 trials for non-small cell lung cancer and other advanced tumors.